What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2022 Apr 25

PMID 35466937

Authors

Fred B Ketchum

Claire M Erickson

Nathaniel A Chin

Carey E Gleason

Nickolas H Lambrou

Susan Flowers Benton

Lindsay R Clark

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) begins with an asymptomatic "preclinical" phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Research is increasingly focused on validating biomarkers to improve reliable diagnosis and timely clinical treatment of AD. Most preclinical biomarker research lacks adequate representation of Black/African American and other racially and ethnically minoritized individuals, limiting the applicability of data to these groups. This may exacerbate existing disparities by hindering diagnosis and treatment among racially and ethnically minoritized individuals.

Objective: Understand the factors influencing willingness of Blacks/African Americans to participate in AD biomarker research and identify opportunities to improve enrollment.

Methods: We enrolled Blacks/African Americans (N = 145) between 46-85 years of age who had previously participated in AD research. Participants gave open-ended responses to a vignette describing a hypothetical biomarker research study. Using qualitative content analysis, we identified themes that motivated and discouraged enrollment in AD biomarker research.

Results: Participant responses were categorized into several themes. Themes motivating participation included a desire to know their biomarker results and to support research. Major themes discouraging participation included concerns about potential negative psychological outcomes to learning one's increased risk for AD, doubt about the usefulness of testing, and worry about the potential physical harms of testing.

Conclusion: Understanding themes motivating and discouraging AD preclinical biomarker research participation may inform research material development, approach to community engagement, and/or trial design to increase enrollment of Blacks/African Americans.

Citing Articles

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).

Mormino E, Biber S, Rahman-Filipiak A, Arfanakis K, Clark L, Dage J Alzheimers Dement. 2024; 21(1):e14383.

PMID: 39588767 PMC: 11772703. DOI: 10.1002/alz.14383.

Elevated plasma p-tau231 is associated with reduced generalization and medial temporal lobe dynamic network flexibility among healthy older African Americans.

Budak M, Fausto B, Osiecka Z, Sheikh M, Perna R, Ashton N Alzheimers Res Ther. 2024; 16(1):253.

PMID: 39578853 PMC: 11583385. DOI: 10.1186/s13195-024-01619-0.

Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer's Disease Trial.

Ritchie M, Raman R, Ernstrom K, Wang S, Donohue M, Aisen P J Prev Alzheimers Dis. 2024; 11(6):1563-1571.

PMID: 39559869 PMC: 11573807. DOI: 10.14283/jpad.2024.157.

Referral Sources Across Racial and Ethnic Groups at Alzheimer's Disease Research Centers.

Chan C, Lane K, Gao S, Adeoye-Olatunde O, Biber S, Glover C J Alzheimers Dis. 2024; 101(4):1167-1176.

PMID: 39365322 PMC: 11492003. DOI: 10.3233/JAD-240485.

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.

Walter S, Langford O, Jimenez-Maggiora G, Abdel-Latif S, Rissman R, Grill J J Prev Alzheimers Dis. 2024; 11(5):1435-1444.

PMID: 39350391 PMC: 11436450. DOI: 10.14283/jpad.2024.101.

References

Gilmore-Bykovskyi A, Jin Y, Gleason C, Flowers-Benton S, Block L, Dilworth-Anderson P . Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review. Alzheimers Dement (N Y). 2020; 5:751-770. PMC: 6944728. DOI: 10.1016/j.trci.2019.09.018. View

Kim H, Lingler J . Disclosure of amyloid PET scan results: A systematic review. Prog Mol Biol Transl Sci. 2019; 165:401-414. DOI: 10.1016/bs.pmbts.2019.05.002. View

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

Blazel M, Lazar K, Van Hulle C, Ma Y, Cole A, Spalitta A . Factors Associated with Lumbar Puncture Participation in Alzheimer's Disease Research. J Alzheimers Dis. 2020; 77(4):1559-1567. PMC: 7683076. DOI: 10.3233/JAD-200394. View

Cox C, Ryan B A M, Gillen D, Grill J . A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. Am J Geriatr Psychiatry. 2018; 27(3):322-332. PMC: 6387840. DOI: 10.1016/j.jagp.2018.10.016. View

Lautenbach D, Christensen K, Sparks J, Green R . Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet. 2013; 14:491-513. PMC: 3862080. DOI: 10.1146/annurev-genom-092010-110722. View

Barnes L, Bennett D . Alzheimer's disease in African Americans: risk factors and challenges for the future. Health Aff (Millwood). 2014; 33(4):580-6. PMC: 4084964. DOI: 10.1377/hlthaff.2013.1353. View

Wake T, Tabuchi H, Funaki K, Ito D, Yamagata B, Yoshizaki T . Disclosure of Amyloid Status for Risk of Alzheimer Disease to Cognitively Normal Research Participants With Subjective Cognitive Decline: A Longitudinal Study. Am J Alzheimers Dis Other Demen. 2020; 35:1533317520904551. PMC: 10623980. DOI: 10.1177/1533317520904551. View

Williams M, Scharff D, Mathews K, Hoffsuemmer J, Jackson P, Morris J . Barriers and facilitators of African American participation in Alzheimer disease biomarker research. Alzheimer Dis Assoc Disord. 2010; 24 Suppl:S24-9. PMC: 2939138. DOI: 10.1097/WAD.0b013e3181f14a14. View

10.

Carmona S, Hardy J, Guerreiro R . The genetic landscape of Alzheimer disease. Handb Clin Neurol. 2018; 148:395-408. DOI: 10.1016/B978-0-444-64076-5.00026-0. View

11.

Howell J, Parker M, Watts K, Kollhoff A, Tsvetkova D, Hu W . Research Lumbar Punctures among African Americans and Caucasians: Perception Predicts Experience. Front Aging Neurosci. 2016; 8:296. PMC: 5133251. DOI: 10.3389/fnagi.2016.00296. View

12.

Chin A, Negash S, Hamilton R . Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011; 25(3):187-95. PMC: 3396146. DOI: 10.1097/WAD.0b013e318211c6c9. View

13.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

14.

Mooldijk S, Licher S, Wolters F . Characterizing Demographic, Racial, and Geographic Diversity in Dementia Research: A Systematic Review. JAMA Neurol. 2021; 78(10):1255-1261. DOI: 10.1001/jamaneurol.2021.2943. View

15.

Brenman N, Milne R . Lived time and the affordances of clinical research participation. Sociol Health Illn. 2021; 43(9):2031-2048. DOI: 10.1111/1467-9566.13374. View

16.

Johnson S, Koscik R, Jonaitis E, Clark L, Mueller K, Berman S . The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimers Dement (Amst). 2018; 10:130-142. PMC: 5755749. DOI: 10.1016/j.dadm.2017.11.007. View

17.

Grill J, Raman R, Ernstrom K, Sultzer D, Burns J, Donohue M . Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020; 77(12):1504-1513. PMC: 7418046. DOI: 10.1001/jamaneurol.2020.2734. View

18.

Ranganathan M, Bhopal R . Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. PLoS Med. 2005; 3(3):e44. PMC: 1324792. DOI: 10.1371/journal.pmed.0030044. View

19.

Denny A, Streitz M, Stock K, Balls-Berry J, Barnes L, Byrd G . Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018. Alzheimers Dement. 2020; 16(12):1734-1744. PMC: 7887120. DOI: 10.1002/alz.12160. View

20.

Vanderschaeghe G, Schaeverbeke J, Vandenberghe R, Dierickx K . Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context. Neuroethics. 2017; 10(2):281-297. PMC: 5486502. DOI: 10.1007/s12152-017-9313-z. View